FRYL expression is significantly higher in CRPC and NEPC patient tumor samples when compared to prostate benign tumors (Wilcoxon test; benign vs. CRPC p = 6.6e-05, benign vs. NEPC p = 0.00025, PCa vs. CRPC p = 8.5e-07, and PCa vs. NEPC p = 4.5e-05). This evidence concerns the gene FRYL and benign neoplasm.